Article
Boceprevir for untreated chronic HCV genotype 1 infection.
The New England journal of medicine - 31 Mar 2011
Poordad Fred, McCone Jonathan, Bacon Bruce R, Bruno Savino, Manns Michael P, Sulkowski Mark S, Jacobson Ira M, Reddy K Rajender, Goodman Zachary D, Boparai Navdeep, DiNubile Mark J, Sniukiene Vilma, Brass Clifford A, Albrecht Janice K, Bronowicki Jean-Pierre
Abstract excerpt
BACKGROUND: Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies. METHODS: We conducted a double-blind study in which previously...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.